CN113278547A - 一种禽乳杆菌y122及其对抗多种病原菌的医用用途 - Google Patents

一种禽乳杆菌y122及其对抗多种病原菌的医用用途 Download PDF

Info

Publication number
CN113278547A
CN113278547A CN202110530911.5A CN202110530911A CN113278547A CN 113278547 A CN113278547 A CN 113278547A CN 202110530911 A CN202110530911 A CN 202110530911A CN 113278547 A CN113278547 A CN 113278547A
Authority
CN
China
Prior art keywords
lactobacillus
avium
active substance
bacteriostatic
cctcc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110530911.5A
Other languages
English (en)
Other versions
CN113278547B (zh
Inventor
杨勇军
颜世卿
陈巍
马轲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jilin University
Original Assignee
Jilin University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jilin University filed Critical Jilin University
Priority to CN202110530911.5A priority Critical patent/CN113278547B/zh
Publication of CN113278547A publication Critical patent/CN113278547A/zh
Application granted granted Critical
Publication of CN113278547B publication Critical patent/CN113278547B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/04Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

本发明公开一种禽乳杆菌Y122及其对抗多种病原菌的医用用途,分类命名为:Lactobacillus aviarius,保藏单位:中国典型培养物保藏中心(CCTCC),地址:中国.武汉.武汉大学,保藏日期:2020年12月14日,保藏编号:CCTCC NO:M 2020900;为一种新的禽乳杆菌,具有广谱抗菌作用,可以用于制备广谱抗菌药物,是一种安全、高效、绿色的天然抗生素替代品,适用于食品工业、畜牧养殖业、保障人类公共健康等领域。

Description

一种禽乳杆菌Y122及其对抗多种病原菌的医用用途
技术领域
本发明公开一种禽乳杆菌Y122,同时还公开了该禽乳杆菌所产的细菌素的制备方法及其在抑菌方面的应用,属于微生物技术领域。
背景技术
现今社会,随着科技的不断发展,工业化的养殖技术、食品加工逐渐普及,随之而来的是食品添加剂、化学防腐剂的大量使用,造成人体的过敏反应及菌群失调;抗生素的滥用以及动物源食品中的药物残留导致耐药菌株的不断产生;上述现象严重威胁了食品安全、畜牧生产及公共健康。因此,需找安全、高效、绿色的天然抗生素替代品成为发展食品工业、畜牧养殖业、保障人类公共健康的时代趋势。乳酸菌作为被公认为是安全的食品级微生物,自古以来就与食品发酵及保存相关联,如今,它们更是最重要的工业微生物类。目前这些乳酸菌大多分离自发酵食品以及环境。同时,乳酸菌是健康机体的肠道优势菌群,能够联合肠黏膜形成生物屏障,阻止外源致病菌入侵机体,同时分泌抑菌代谢物,保障动物正常的生理机能。因此,肠道乳酸菌在抵抗病原体入侵、免疫调节方面相比于外源乳酸菌更有优势。
乳酸菌产生的细菌素作为天然防腐剂的应用受到了广泛的关注,并得到广泛认可。现阶段已经分离出了几种具有潜在工业应用价值的细菌素,并对其进行了表征,并且当热敏感食品在运输过程中冷链条件不足时,它们可以用于保存食品。但是目前只有乳链球菌素Nisin被批准为食品防腐剂,且Nisin对革兰氏阴性菌和真菌的抑制效果较弱,而其他乳酸菌细菌素还存在品种单一,产量低等问题。因此,寻找新型的乳酸菌素,并对其进行详尽的基础研究和开发应用研究,对推动乳酸菌细菌素在食品工业中的应用具有重要意义。
发明内容
本发明提供了一种禽乳杆菌Y122,所述禽乳杆菌具有广谱抗菌作用。
本发明提供了一种禽乳杆菌Y122的医用用途,所述禽乳杆菌可产生的抑菌活性物质。
本发明所述的一种禽乳杆菌Y122,分类命名为:禽乳杆菌Y122;Lactobacillusaviarius strain Y122,保藏单位:中国典型培养物保藏中心(CCTCC),地址:中国.武汉.武汉大学,保藏日期:2020年12月14日,保藏编号:CCTCC NO:M 2020900。
本发明所述的禽乳杆菌Y122的抑菌活性物质的制备方法,包括以下步骤:
将禽乳杆菌Y122按1%接种至MRS液体培养基中,37℃厌氧发酵84小时,8000rpm,4℃离心10分钟,上清经0.22μm滤膜过滤即得发酵液。
将上述发酵液与丙酮按照1:4体积比混合,4℃静置沉淀2小时,12000rpm,4℃离心20分钟,所得沉淀即为粗提活性物质。
将上述粗提活性物质用葡聚糖凝胶G-50层析柱进行分离,所得即为抑菌活性物质粗提液;
将上述分离物质用制备型HPLC进行分离,所得即为抑菌活性物质。
本发明的积极效果在于:
公开了一种新的禽乳杆菌Y122,该禽乳杆菌具有广谱抗菌作用,可以用于制备广谱抗菌药物,是一种安全、高效、绿色的天然抗生素替代品,适用于食品工业、畜牧养殖业、保障人类公共健康等领域。
附图说明
图1 禽乳杆菌Y122菌落形态;
图2 禽乳杆菌Y122的进化树;
图3 禽乳杆菌Y122的抑菌活性鉴定;
图4 禽乳杆菌Y122生长曲线、发酵液pH变化及抑菌效果;
图5 禽乳杆菌Y122抑菌粗提物质凝胶过滤层析检测图;
图6 禽乳杆菌Y122 抑菌活性物质制备型高效液相色谱检测图。
具体实施方式
以下实施例用于说明本发明,但不用来限制本发明的范围。若未特别指明,实施例中所用的技术手段为本领域人员所熟知的常规手段。下述实施例中所使用的材料、试剂等如无特殊说明,均可从商业途径得到。本发明实施例采用了牛津杯琼脂扩散法检测抑菌活性。
实施例1
所述禽乳杆菌Y122的分离鉴定:
材料与设备:
菌种来源:本实施例中所分离菌种来源于5月龄三黄鸡盲肠肠道,三黄鸡购自吉林省长春市绿园区四季青市场。
抑菌试验所用指示菌为本实验室保藏的鼠伤寒沙门氏菌(SalmonellaTyphimurium)SL1344、鸡白痢沙门氏菌(Salmonella Pullorum)ATCC19945、金黄色葡萄球菌(Staphylococcus aureus)USA300_TCH1516、铜绿假单胞菌(Pseudomonas aeruginosa)ATCC27853、肺炎克雷伯菌(Klebsiella pneumoniae)ATCC700603、单增李斯特菌(Listeriamonocytogenes)ATCC19115、屎肠球菌(Enterococcus faecalis)4P-SA、白色念珠菌(Candida Albicans)CMCC 98001。
MRS培养基购自青岛海博生物,称取52.24g粉末,加热溶解于1000mL蒸馏水中,固体培养基添加1.5%琼脂,118℃高压灭菌15分钟即得。
TSB培养基购自青岛海博生物,称取 30g粉末,加热搅拌溶解于1000mL蒸馏水中,固体培养基添加1.5%琼脂,121℃高压灭菌15分钟即得。
YM培养基购自青岛海博生物,称取21g粉末,加热溶解于1000mL蒸馏水中,固体培养基添加1.5%琼脂,121℃高压灭菌15分钟即得。
LB培养基:蛋白胨,10g、酵母提取物,5g、氯化钠,10g,加热溶解于1000mL蒸馏水中,固体培养基添加1.5%琼脂,121℃高压灭菌15分钟即得。
YCFA培养基:脑心浸出液肉汤(BHI,青岛海博),18.5g、酵母提取物,5g、TSB培养基,15g、葡萄糖,0.5g、磷酸氢二钾,2.5g、氯化钯,0.33g、黏蛋白,4g、蒸馏水1000mL,固体培养基添加1.5%琼脂,115℃高压灭菌30分钟,冷却至45℃继续加入5%(v/v)胎牛血清、维生素K3,5μg、氯化血红素,10μg、微量盐,1mL、D-生物素,10μg、维生素B12,10μg、吡多胺(维生素B6),100μg、叶酸(维生素B9),50μg、L-半胱氨酸盐酸盐—水合物,0.6g即得。
实验方法:
禽乳杆菌Y122的分离:将5月龄三黄鸡采用急性失血法处死,剖开腹腔,暴露肠道,用止血钳夹住所需盲肠两端,用手术剪沿止血钳外端剪开,拿出肠段。在超净台中,用手术剪剪开盲肠,暴露肠内容物,用手术刀轻柔刮去肠内容物,换刀继续刮取肠黏膜,PBS倍比稀释后,平板划线于YCFA琼脂平板,37℃厌氧培养48小时,观察发现菌落形态呈乳白色圆形,中间略微隆起,半透明、边缘整齐。挑取单菌落至YCFA液体中继续培养,重复平板划线,直至菌落单一。
菌种活化鉴定及保藏:初步判定为禽乳杆菌的单菌落,接种到3mL YCFA液体培养基中于37℃厌氧培养48h,再以1%(v/v)接种量进行2次传代培养。活化后编号Y122保种,16SrRNA测序,序列上传NCBI blast进行比对,应用软件MEGA7做菌株进化树。取500μL菌液加入500μL灭菌50%甘油YCFA于-80℃保藏菌株。
禽乳杆菌Y122的扩增培养:将保藏在-80℃甘油管中的Y122菌株,于MRS固体培养基平板上划线活化,37℃厌氧培养48h后,挑取单菌落接种于MRS液体培养基中,37℃厌氧培养48h即得扩增菌液。
指示菌的培养:将保藏在-80℃甘油管中的各种指示菌菌种,分别划线于LB固体培养基平板、TSB固体培养基平板、YM固体培养基平板,在各自的最适温度下培养至出现明显单菌落,挑取单菌落接种于对应的液体培养基中摇床振荡培养至对数期。用PBS调整菌体浓度至OD600=1,4℃保存备用。
禽乳杆菌Y122抑菌鉴定:将培养48h的Y122扩增菌液8000rpm,4℃离心10min,上清用0.22μm滤膜过滤得到无细胞发酵液,将培养好的指示菌按1%(v/v)接种至相应40℃高压灭菌后的琼脂培养基中,轻柔并迅速混合均匀后倒板,待琼脂培养基凝固后,在表面放置牛津杯,每个牛津杯内加入200μL上述无细胞发酵液,在生物洁净工作台中扩散3h后,37℃培养9h,检测是否有抑菌环出现并用游标卡尺测量抑菌环直径,每个指示菌需要进行至少3次重复,结果见表1,禽乳杆菌Y122菌落形态等表征参见图1~图6所示。
表1 禽乳杆菌Y122抑菌鉴定
Figure RE-DEST_PATH_IMAGE001
实施例2
禽乳杆菌Y122所产细菌素的分离鉴定:
实验方法:
根据实施例一,下述实验抑菌活性检测指示菌均为鼠伤寒沙门氏菌(SalmonellaTyphimurium)SL1344,并在每一纯化步骤后均进行抑菌活性监测以保证禽乳杆菌Y122所产细菌素的成功分离。
禽乳杆菌Y122抑菌发酵液的制备:将保藏在-80℃甘油管中的Y122菌株,于MRS固体培养基平板上划线活化,37℃厌氧培养48h后,挑取单菌落接种于MRS液体培养基中,37℃厌氧培养48h,菌液按1%(v/v)接种至500mL的MRS液体培养基中,37℃厌氧培养84h后,8000rpm,4℃离心10min,上清用0.22μm滤膜过滤即得抑菌发酵液。
禽乳杆菌Y122抑菌粗提物质的制备:将丙酮-20℃预冷,之后与抑菌发酵液按4:1(v/v)比例混合,轻柔振荡混匀后,4℃沉淀2h,12000rpm,4℃离心15min,沉淀即为抑菌粗提物质。
禽乳杆菌Y122抑菌粗提物质的纯化:将抑菌粗提物质按一定浓度用超纯水溶解,上样至凝胶过滤层析柱,层析柱填料为葡聚糖凝胶G50(Sephadex G-50),流动相为超纯水,手动收集流出组分,并用分光光度计在280nm波长进行检测。
将凝胶过滤层析后检测具有抑菌活性的组分,上样至制备型HPLC,进行进一步分离纯化。液相仪器为Waters 2535制备型高效液相色谱仪,流动相为乙腈—0.1% TFA水溶液。洗脱条件为梯度洗脱。将HPLC收集组分冻干,做活性检测。
禽乳杆菌Y122抑菌活性物质的抑菌效果鉴定:使用微量肉汤稀释法对该物质抑菌谱以及MIC进行检测。MIC结果见表2.
表2 禽乳杆菌Y122细菌素抑菌谱及MIC
Figure RE-DEST_PATH_IMAGE002
序列表
<110> 吉林大学
<120> 一种禽乳杆菌Y122及其对抗多种病原菌的医用用途
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1106
<212> RNA
<213> 禽乳杆菌(Lactobacillus aviaries)
<400> 1
gcagcgaacg agaacacacc gaggcgcacc accgaagaaa cgagggcgga cggggagaac 60
acggggaacc gcccaaaaga aggggaaaca ggaaacaaag caaaccgaaa ccagagaccg 120
caggcaagaa aagggggcac gcggaggacc cgcggcgaaa cagggaggga acggccacca 180
agggagaacg agccgaggag agacgacggc cacaagggac gagacacggc ccaacccacg 240
ggaggcagca gagggaaccc acaagggcgc aagccgagga gcaacgccgc ggaagaagaa 300
ggccggacga aaacggagag aagaaagaga aagaacgaac acgacggaca accagcaagc 360
acggcaacac ggccagcagc cgcggaaacg aggggcaagc ggccggaagg gcgaaaggga 420
acgcaggcgg aagcgaggaa agcccggcaa ccggagaggc aggaaacgga agacgaggca 480
gaagaggaga gggaacccag gagcgggaaa gcgagaaagg aagaacacca gggcgaaagc 540
ggcccggcga acgacgcgag gcgaaagcag ggagcgaaca ggaagaaccc ggagccagcc 600
gaaacgagaa gcagggggag ggccgcccca ggccgcagca acgcaaaagc accgccgggg 660
agacgaccgc aagggaaacc aaaggaagac gggggcccgc acaagcgggg agcagggaac 720
gaagcaacgc gaagaaccac caggcgacac gaccaccaag agaaggcccc ggggacaaaa 780
gacagggggc aggcgcgcag ccggcggaga ggggaagccc gcaacgagcg caacccggca 840
ggccacaagg ggcaccggcg agacgccggg acaaaccgga ggaagggggg agacgcaagc 900
acagccccag accgggcaca cacggcacaa ggacgaacaa cgagcgcgaa accgcgagga 960
agcaaccaaa gcgccagcgg agcaggcgca accgccgcag aagcggaacg cagaacgcgg 1020
acagcagccg cgggaaacgc ccgggccgac acaccgcccg cacaccagag aggaacaccc 1080
aaagccgggg agaaccagga gcagcc 1106

Claims (4)

1.一种禽乳杆菌Y122,于2020年12月14日在中国典型培养物保藏中心(CCTCC)保藏,保藏编号:CCTCC NO:M 2020900;分类命名为:禽乳杆菌Y122;Lactobacillus aviariusstrain Y122。
2.如权利要求1所述禽乳杆菌Y122产生的抑菌活性物质的制备方法,包括以下步骤:
1)将禽乳杆菌Y122按1%接种至MRS液体培养基中,37℃厌氧发酵84小时,8000rpm,4℃离心10分钟,上清经0.22μm滤膜过滤即得发酵液;
2)将上述发酵液与丙酮按照1:4体积比混合,4℃静置沉淀2小时,12000rpm,4℃离心20分钟,所得沉淀即为粗提活性物质;
3)将上述粗提活性物质用葡聚糖凝胶G-50层析柱进行分离,所得即为抑菌活性物质粗提液;
4)将上述分离物质用制备型HPLC进行分离,所得即为抑菌活性物质。
3.如权利要求1所述的一种禽乳杆菌Y122产生的抑菌活性物质在制备广谱抗菌药物中的用途。
4.一种药物制剂,其特征在于以权利要求1所述的一种禽乳杆菌Y122产生的抑菌活性物质为活性成分,同时含有一种或多种药学上可接受的载体物质和/或辅剂。
CN202110530911.5A 2021-05-15 2021-05-15 一种禽乳杆菌y122及其对抗多种病原菌的医用用途 Active CN113278547B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110530911.5A CN113278547B (zh) 2021-05-15 2021-05-15 一种禽乳杆菌y122及其对抗多种病原菌的医用用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110530911.5A CN113278547B (zh) 2021-05-15 2021-05-15 一种禽乳杆菌y122及其对抗多种病原菌的医用用途

Publications (2)

Publication Number Publication Date
CN113278547A true CN113278547A (zh) 2021-08-20
CN113278547B CN113278547B (zh) 2022-06-07

Family

ID=77279316

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110530911.5A Active CN113278547B (zh) 2021-05-15 2021-05-15 一种禽乳杆菌y122及其对抗多种病原菌的医用用途

Country Status (1)

Country Link
CN (1) CN113278547B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116042482A (zh) * 2023-02-16 2023-05-02 中国农业大学 一种鸟乳杆菌及其在制备治疗或缓解高尿酸血症的产品中的应用

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1772000A (zh) * 2005-10-27 2006-05-17 吉林大学 用嗜酸乳杆菌制备能预防和治疗慢性胃病的保健品或药物
WO2008155120A2 (en) * 2007-06-20 2008-12-24 Actogenix Nv Methods and compositions for treating mucositis
US20110256232A1 (en) * 2008-10-28 2011-10-20 Nofima Ingrediens Antimicrobial composition from copepods
US20130323819A1 (en) * 2010-08-05 2013-12-05 Lennart Hammarström Expression of antibody or a fragment thereof in lactobacillus
DE102013226874A1 (de) * 2013-12-20 2014-04-17 Henkel Ag & Co. Kgaa Konservierungsmittel für Kosmetika
CN104797705A (zh) * 2012-05-21 2015-07-22 杜邦营养生物科学有限公司 具有抗真菌性的乳杆菌属菌株
CN109837222A (zh) * 2017-11-28 2019-06-04 广州中国科学院先进技术研究所 一种乳酸杆菌培养基及其制备方法和乳酸杆菌的培养方法
WO2019202137A1 (en) * 2018-04-20 2019-10-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treating pseudomonas aeruginosa respiratory tract infections
CN110575491A (zh) * 2018-06-07 2019-12-17 珠海岐微生物科技有限公司 贝母在调节肠道微生物中的用途
WO2020177857A1 (en) * 2019-03-04 2020-09-10 Aurealis Pharma Ag Chloride-inducible prokaryotic expression system
CN112752849A (zh) * 2018-05-18 2021-05-04 迈克必斯生物系统公司 用于核酸检测的质量对照组合物和全生物体对照材料
CN113151364A (zh) * 2021-05-26 2021-07-23 吉林大学 一种从鸡肠源唾液乳杆菌分离的抑菌活性物质及应用
WO2021163345A1 (en) * 2020-02-11 2021-08-19 Tenza, Inc. Bio-therapeutics for detection, diagnosis and treatment of diseases associated with mucosal bleeding

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1772000A (zh) * 2005-10-27 2006-05-17 吉林大学 用嗜酸乳杆菌制备能预防和治疗慢性胃病的保健品或药物
WO2008155120A2 (en) * 2007-06-20 2008-12-24 Actogenix Nv Methods and compositions for treating mucositis
US20110256232A1 (en) * 2008-10-28 2011-10-20 Nofima Ingrediens Antimicrobial composition from copepods
US20130323819A1 (en) * 2010-08-05 2013-12-05 Lennart Hammarström Expression of antibody or a fragment thereof in lactobacillus
CN104797705A (zh) * 2012-05-21 2015-07-22 杜邦营养生物科学有限公司 具有抗真菌性的乳杆菌属菌株
DE102013226874A1 (de) * 2013-12-20 2014-04-17 Henkel Ag & Co. Kgaa Konservierungsmittel für Kosmetika
CN109837222A (zh) * 2017-11-28 2019-06-04 广州中国科学院先进技术研究所 一种乳酸杆菌培养基及其制备方法和乳酸杆菌的培养方法
WO2019202137A1 (en) * 2018-04-20 2019-10-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treating pseudomonas aeruginosa respiratory tract infections
CN112752849A (zh) * 2018-05-18 2021-05-04 迈克必斯生物系统公司 用于核酸检测的质量对照组合物和全生物体对照材料
CN110575491A (zh) * 2018-06-07 2019-12-17 珠海岐微生物科技有限公司 贝母在调节肠道微生物中的用途
WO2020177857A1 (en) * 2019-03-04 2020-09-10 Aurealis Pharma Ag Chloride-inducible prokaryotic expression system
WO2021163345A1 (en) * 2020-02-11 2021-08-19 Tenza, Inc. Bio-therapeutics for detection, diagnosis and treatment of diseases associated with mucosal bleeding
CN113151364A (zh) * 2021-05-26 2021-07-23 吉林大学 一种从鸡肠源唾液乳杆菌分离的抑菌活性物质及应用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KAZUMI KITA等: "Influence of Propolis Residue on the Bacterial Flora in the Cecum of Nanbu Kashiwa", 《J. POULT. SCI.》, vol. 51, 25 November 2013 (2013-11-25) *
YI HONG等: "Lactobacillus salivarius and Lactobacillus agilis feeding regulates intestinal stem cells activity by modulating crypt niche in hens", 《APPLIED MICROBIOLOGY AND BIOTECHNOLOGY》, vol. 105, 28 October 2021 (2021-10-28), XP037617784, DOI: 10.1007/s00253-021-11606-2 *
YUQING FENG等: "Metagenome-assembled genomes and gene catalog from the chicken gut microbiome aid in deciphering antibiotic resistomes", 《COMMUNICATIONS BIOLOGY》, vol. 4, 18 November 2021 (2021-11-18) *
刘彩琴等: "黄酒米浆水中抗菌乳酸菌的筛选及特性分析", 《食品工业科技》, no. 09, 6 December 2019 (2019-12-06) *
赵乃昕等: "《医学细菌名称及分类鉴定》", 31 March 2013, pages: 214 - 219 *
龙淼等: "犊牛瘤胃内黏膜乳杆菌的分离鉴定及生物学特性研究", 《畜牧与兽医》, no. 03, 10 March 2009 (2009-03-10) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116042482A (zh) * 2023-02-16 2023-05-02 中国农业大学 一种鸟乳杆菌及其在制备治疗或缓解高尿酸血症的产品中的应用
CN116042482B (zh) * 2023-02-16 2024-10-18 中国农业大学 一种鸟乳杆菌及其在制备治疗或缓解高尿酸血症的产品中的应用

Also Published As

Publication number Publication date
CN113278547B (zh) 2022-06-07

Similar Documents

Publication Publication Date Title
CN111235070B (zh) 一株母乳婴儿源植物乳杆菌bf_15及其应用
Wang et al. Sensitivity of Escherichia coli to seaweed (Ascophyllum nodosum) phlorotannins and terrestrial tannins
CN1798831B (zh) 含有与丹宁组合的植物乳杆菌菌株的组合物和新植物乳杆菌菌株
Toushik et al. Korean kimchi-derived lactic acid bacteria inhibit foodborne pathogenic biofilm growth on seafood and food processing surface materials
Gupta et al. Probiotic potential of bacteriocin-producing Enterococcus hirae strain LD3 isolated from dosa batter
Bindu et al. Identification and in vitro evaluation of probiotic attributes of lactic acid bacteria isolated from fermented food sources
Khouadja et al. Selection of lactic acid bacteria as candidate probiotics for Vibrio parahaemolyticus depuration in pacific oysters (Crassostrea gigas)
CN108048352B (zh) 一种产抑菌物质的屎肠球菌xc2及其筛选方法与应用
CN116590172B (zh) 乳酸片球菌glp06及其应用和产品
CN110577912A (zh) 一种格氏乳杆菌及其在制备发酵乳中的应用
Sa et al. Production and antibacterial activity of bacteriocin by Lactobacillus paracasei isolated from donkey milk
Perumal et al. Partial purification and characterization of bacteriocin produced by Enterococcus faecalis DU10 and its probiotic attributes
Ghalem Antioxidant and antimicrobial activities of exopolysaccharides from yoghurt starter
CN113278547B (zh) 一种禽乳杆菌y122及其对抗多种病原菌的医用用途
CN116463264A (zh) 一种具有结肠癌细胞生长抑制作用的植物乳杆菌及其应用
Amini et al. Isolation and characterization of exopolysaccharide derived from Lacticaseibacillus paracasei AS20 (1) with probiotic potential and evaluation of its antibacterial activity
Nair et al. Antimicrobial Activity of the protein fraction obtained in the extraction of Curcumin
KR20200051953A (ko) 락토바실러스 살리바리우스 v133 균주, 상기 균주의 사균체 또는 상기 균주의 대사산물을 유효성분으로 함유하는 알코올성 위염의 예방, 개선 또는 치료용 조성물
CN108404114B (zh) 一种金黄色葡萄球菌抗菌剂及其制备方法和应用
Niamah et al. Antibacterial spectrum of produced reuterin from new isolates of Lactobacillus reuteri
RU2298032C2 (ru) ШТАММ БАКТЕРИЙ Bacillus subtilis 1719-ПРОДУЦЕНТ АНТАГОНИСТИЧЕСКИ АКТИВНОЙ БИОМАССЫ В ОТНОШЕНИИ БОЛЕЗНЕТВОРНЫХ МИКРООРГАНИЗМОВ, А ТАКЖЕ ПРОТЕОЛИТИЧЕСКИХ, АМИЛОЛИТИЧЕСКИХ И ЛИПОЛИТИЧЕСКИХ ФЕРМЕНТОВ
Pasteris et al. Characterization of the beneficial properties of lactobacilli isolated from bullfrog (Rana catesbeiana) hatchery
CN114085791A (zh) 一种戊糖片球菌He10-a-1及其用途
CN115058367A (zh) 一株戊糖乳杆菌(Lactobacillus pentosus)068-1及其应用
Nguyen et al. Biological Activities of Tetrodotoxin‐Producing Enterococcus faecium AD1 Isolated from Puffer Fishes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant